Rituximab, Anti-CD20, Induces In Vivo Cytokine Release But Does Not Impair Ex Vivo T-Cell Responses

This publication has 17 references indexed in Scilit:

• A three-arm study comparing immediate tacrolimus therapy with antithymocyte globulin induction therapy followed by tacrolimus or cyclosporine A in adult renal transplant recipients1
  Transplantation, 2003
• Rituximab: clinical development and future directions
  Expert Opinion on Biological Therapy, 2002
• CD20 antibody (C2B8)-induced apoptosis of lymphoma cells promotes phagocytosis by dendritic cells and cross-priming of CD8+ cytotoxic T cells
  Leukemia, 2001
• Consequences of Cell Death
  The Journal of Experimental Medicine, 2000
• CONTRIBUTION OF DONOR-SPECIFIC ANTIBODIES TO ACUTE ALLOGRAFT REJECTION
  Transplantation, 1998
• Mechanism of first-dose cytokine-release syndrome by CAMPATH 1-H: involvement of CD16 (FcgammaRIII) and CD11a/CD18 (LFA-1) on NK cells.
  Journal of Clinical Investigation, 1996
• Relationships Between B Cell Cytokine Production in Secondary Lymphoid Follicles and Apoptosis of Germinal Center B Lymphocytes
  The International Journal of Cell Cloning, 1995
• Reversal of experimental autoimmune encephalomyelitis by a soluble peptide variant of a myelin basic protein epitope: T cell receptor antagonism and reduction of interferon gamma and tumor necrosis factor alpha production.
  The Journal of Experimental Medicine, 1994
• REMOVAL OF LYMPHOCYTOTOXIC ANTIBODIES BY PRETRANSPLANT IMMUNOADSORPTION THERAPY IN HIGHLY SENSITIZED RENAL TRANSPLANT RECIPIENTS
  Transplantation, 1991
• IN VIVO CELL ACTIVATION FOLLOWING OKT3 ADMINISTRATION
  Transplantation, 1990